Hemophilia Market Will Be Worth $15.2 Billion By 2024: Grand View Research, Inc.
Global hemophilia market is expected to reach USD 15.2
billion by 2024, according to a new report by Grand View Research, Inc.
Increasing need for diagnosis of the target population in order to initiate
prophylaxis treatment and supportive government programs is expected to be the
vital impact rendering driver.
The market players are predicted to adopt strategies such as
pipeline product development and geographic expansion in underdeveloped and
developing regions, such as Middle Eastern and West African countries.
As of 2015, federal bodies such as the World Federation
Hemophilia have vast information and treatment regulation in about 172
countries, of which 20 were added in 2013,including Nigeria, Togo, Mali,
Zambia, Mauritania, and others.
Competitive pricing strategy is a vital factor promoting
market players’ growth over the forecast period. For instance, Biogen launched
Eloctate in 2014 in the U.S. at a lower price than the existing vastly used
drug Advate.
Browse full research report on Global Hemophilia Market: http://www.grandviewresearch.com/industry-analysis/hemophilia-treatment-industry
Further Key Findings From the Study Suggest:
- Hemophilia
B is expected to grow at a rapid rate of over 6.0% during the forecast
period. Higher emphasis on pipeline products with an extended half-life
and increasing incidence of hemophilia B affected patients are expected to
be the prominent growth factors.
- On-demand
treatment dominated the segment over the forecast period and is expected
to contribute more than 50.0% by 2024. However, prophylaxis is expected to
be the fastest growing segment because of the requirement for better
control of bleeding episodes and growing financial assistance programs by
healthcare providers and industry players.
- For
instance, Grifols has launched the “AlphaNine SD Copay Card” and
“ALPHANATE Copay Program” for immediate enrollment in prophylaxis
treatment by patients.
- On the
basis of therapy, gene therapy is expected to be the fastest growing
segment as a result of increasing R&D and innovations in the field.
Furthermore, replacement therapy is expected to witness lucrative growth
due to the launch of extended half-life versions of currently available
drugs.
- For
instance, Novo Nordisk is working on N8-GP, CSL Behring is working on
CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to
be commercially available around 2017/2018. This is expected to improve
treatment over the forecast period thereby boosting growth.
- Major
market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL
Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are
actively involved in the awareness and treatment programs launched by
regional governments and hemophilia associations. Majority of their
products that are awaiting FDA approval have extended therapeutic use in
adults as well as children.
Browse more reports of this category by Grand View
Research:
http://www.grandviewresearch.com/industry/pharmaceuticals
http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global hemophilia
market on the basis of type, treatment, therapy, and region.
Global Hemophilia Market by Type (USD Million), 2013 –
2024
- Hemophilia
A
- Hemophilia
B
- Hemophilia
C
- Others
Global Hemophilia Market by Treatment (USD Million), 2013
– 2024
- On-demand
- Prophylaxis
Global Hemophilia Market Therapy(USD Million), 2013 –
2024
- Replacement
Therapy
- Immune
Tolerance Induction Therapy
- Gene
Therapy
Hemophilia Market By Region (USD Million), 2013 – 2024
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia-Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- Middle
East and Africa
- South
Africa
- Saudi
Arabia
Access press release of this research report by Grand
View Research: http://www.grandviewresearch.com/press-release/global-hemophilia-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
For more information:
www.grandviewresearch.com
Comments
Post a Comment